Shehata Mahmoud M, Mostafa Ahmed, Teubner Lisa, Mahmoud Sara H, Kandeil Ahmed, Elshesheny Rabeh, Frantz Renate, La Pietra Luigi, Pleschka Stephan, Osman Ahmed, Kayali Ghazi, Chakraborty Trinad, Ali Mohamed A, Mraheil Mobarak Abu
Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Cairo 12622, Egypt.
Institute of Medical Virology, Justus-Liebig University Giessen, 35392 Giessen , Germany.
Vaccines (Basel). 2019 May 28;7(2):46. doi: 10.3390/vaccines7020046.
Vaccination is the most functional medical intervention to prophylactically control severe diseases caused by human-to-human or animal-to-human transmissible viral pathogens. Annually, seasonal influenza epidemics attack human populations leading to 290-650 thousand deaths/year worldwide. Recently, a novel Middle East Respiratory Syndrome Coronavirus emerged. Together, those two viruses present a significant public health burden in areas where they circulate. Herein, we generated a bacterial outer membrane vesicles (OMVs)-based vaccine presenting the antigenic stable chimeric fusion protein of the H1-type haemagglutinin (HA) of the pandemic influenza A virus (H1N1) strain from 2009 (H1N1pdm09) and the receptor binding domain (RBD) of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (OMVs-H1/RBD). Our results showed that the chimeric antigen could induce specific neutralizing antibodies against both strains leading to protection of immunized mice against H1N1pdm09 and efficient neutralization of MERS-CoV. This study demonstrate that OMVs-based vaccines presenting viral antigens provide a safe and reliable approach to protect against two different viral infections.
疫苗接种是预防性控制由人际或动物传人传播的病毒病原体引起的严重疾病的最有效医学干预措施。每年，季节性流感疫情侵袭人群，在全球范围内导致每年29万至65万人死亡。最近，一种新型中东呼吸综合征冠状病毒出现。这两种病毒在其传播的地区共同构成了重大的公共卫生负担。在此，我们制备了一种基于细菌外膜囊泡（OMV）的疫苗，该疫苗呈现了2009年大流行性甲型流感病毒（H1N1）毒株（H1N1pdm09）的H1型血凝素（HA）的抗原稳定嵌合融合蛋白以及中东呼吸综合征冠状病毒（MERS-CoV）的受体结合域（RBD）（OMVs-H1/RBD）。我们的结果表明，嵌合抗原可诱导针对两种毒株的特异性中和抗体，从而保护免疫小鼠免受H1N1pdm09感染，并有效中和MERS-CoV。这项研究表明，呈现病毒抗原的基于OMV的疫苗为预防两种不同的病毒感染提供了一种安全可靠的方法。
